Third Generation EGFR Inhibitor Osimertinib Combined With Pemetrexed or Cisplatin Exerts Long-Lasting Anti-Tumor Effect in EGFR-mutated Pre-Clinical Models of NSCLC
Journal of Experimental and Clinical Cancer Research - United Kingdom
doi 10.1186/s13046-019-1240-x
Full Text
Open PDFAbstract
Available in full text
Date
May 28, 2019
Authors
Publisher
Springer Science and Business Media LLC